BriaCell (BCTX) Therapeutics will be highlighting its overall survival and clinical benefit data in metastatic breast cancer patients including those with CNS metastasis who were treated with the Bria ...

Post-approval overall survival data showed a significant benefit for 32% of the drugs evaluated. Most cancer drugs that have immature overall survival (OS) data when approved by the US Food and Drug ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

Source: Getty Images “In its accelerated approval decisions of new cancer drugs, the FDA might be underestimating the willingness of some patients to wait for greater certainty of survival benefit,” ...